Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Biotechnology

Healthcare
$0.69 -3.42%

-$0.04 today

Market cap
$50.84M
Beta
-0.24
P/E (TTM)
-3.8
EPS (TTM)
-$0.27
52W Low $0.89High $2.09

Volume 0.17M

Average 0.13M

TELO Operating Cash Flow

Cash generated by the company's core business operations during the period.

Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $1.77M (cash outflow) rose 105.5% year over year, ahead of the +15.1% change in trailing-twelve-month operating cash flow. Sequentially, it rose 47.6% from the prior quarter. Over 3 fiscal years it compounded at +98.9% a year.

Context

  • Operating cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +105.5% holds above the trailing-twelve-month pace of +15.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.77M+47.6% QoQ
Last fiscal yearDec 2025
-$3.69M-27.3% YoY
LTMMar 2026
-$4.6M+15.1% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+105.5%——
1 year-27.3%——
3-year CAGR+98.9%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(3.69M) USD
Year-over-year change
+27.3%

Operating Cash Flow vs competitors

How TELO compares with its peers on the latest reported figures

  • TELO's LTM Mar 2026 operating cash flow of $4.6M is the smallest of the 6 companies compared; the peer median is $19.17M.
  • Its year-over-year change of +15.1% is the highest of 6, against a peer median of -17.5%.
  • Over three fiscal years its annual growth of +98.9% compares with a peer median of +15.1%.
TELO Competitors Peer median
Operating Cash Flow for TELO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$94.5M -17.5%——
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$59.11M -51.8%-20.4%39.1%
INMBINmune Bio, Inc.LTM Mar 2026$19.17M -41.4%-0.2%—
EQEquillium, Inc.LTM Mar 2026$18.88M +2.6%+37.6%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$8M +12.4%+30.4%565.5%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$4.6M +15.1%+98.9%—
Peer median (excluding TELO) $19.17M-17.5%+15.1%302.3%

Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(138.13K)(854.15K)(13.07M)(16.53M)(10.41M)
Depreciation & Amortization0004.34M0
Deferred Income Tax00000
Stock-Based Compensation0006.87M5.29M
Change in Working Capital18.74K385.49K113.84K126.47K594.69K
Accounts Receivables00000
Inventory00000
Accounts Payables18.74K0114.56K183.63K(50.77K)
Other Working Capital18.74K385.49K(713)(57.16K)645.46K
Other Non-Cash Items0385.49K9.1M130K840K
Operating Cash Flow(119.4K)(468.66K)(3.86M)(5.07M)(3.69M)
Capital Expenditures(4)0(4)00
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment0462.39K3.17M(101K)0
Common Stock Issued001M6.83M9.55M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities119.4K7.69K(310.38K)(396.65K)155.52K
Financing Cash Flow119.4K470.08K3.86M6.34M9.71M
Effect of Forex Changes00000
Net Change in Cash01.42K(188)1.26M6.02M
Free Cash Flow(119.4K)(468.66K)(3.86M)(5.07M)(3.69M)

Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.